Yamamoto Sosuke, Aoyama Toru, Maezawa Yukio, Hashimoto Itaru, Esashi Ryuki, Kazama Keisuke, Numata Koji, Uchiyama Mamoru, Tamagawa Ayako, Saito Aya, Yukawa Norio
Department of Surgery, Yokohama City University, Yokohama, Japan.
Cancer Diagn Progn. 2025 Jan 3;5(1):115-121. doi: 10.21873/cdp.10419. eCollection 2025 Jan-Feb.
BACKGROUND/AIM: The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with esophageal cancer (EC) who received curative treatment and to clarify the potential of the GINI as a prognostic factor.
Patients who underwent curative resection for EC at Yokohama City University between 2000 and 2020 were consecutively chosen based on their medical records. The GINI was defined as follows: GINI=[C-reactive protein×platelet×monocyte×neutrophil]/[albumin×lymphocyte].
This study included 180 patients. Among them, 67 were categorized into the GINI-low group and 113 were categorized into the GINI-high group, with a cutoff value of 5000. The 3- and 5- year overall survival (OS) rates were 75.6% and 64.9%, respectively, in the GINI-low group and 55.3% and 48.1% in the GINI-high group (p=0.005). According to a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio=2.106, 95% confidence interval=1.252-3.544, p=0.005]. Similar results were observed for RFS. In addition, the GINI affects preoperative tube feeding and the induction rate of neoadjuvant chemotherapy (NAC).
The GINI is a promising biomarker for the treatment and management of EC.
背景/目的：本研究旨在评估全球免疫营养信息指数（GINI）对接受根治性治疗的食管癌（EC）患者的临床影响，并阐明GINI作为预后因素的潜力。
根据病历连续选取2000年至2020年在横滨市立大学接受EC根治性切除术的患者。GINI的定义如下：GINI = [C反应蛋白×血小板×单核细胞×中性粒细胞]/[白蛋白×淋巴细胞]。
本研究纳入180例患者。其中，67例被归类为GINI低分组，113例被归类为GINI高分组，临界值为5000。GINI低分组的3年和5年总生存率（OS）分别为75.6%和64.9%，GINI高分组分别为55.3%和48.1%（p = 0.005）。根据OS的多因素分析，GINI被确定为独立预后因素[风险比 = 2.106，95%置信区间 = 1.252 - 3.544，p = 0.005]。无复发生存期（RFS）也观察到类似结果。此外，GINI影响术前管饲和新辅助化疗（NAC）的诱导率。
GINI是一种有前景的用于EC治疗和管理的生物标志物。
